The most recent trading session ended with Gilead Sciences (GILD) standing at $105.87, reflecting a -1.53% shift from the previouse trading day's closing. This change lagged the S&P 500's daily ...

Gilead Sciences fell 2.52% in premarket trading on the news. The company makes medication for treating HIV and AIDS. Other biopharma firms also fell. The move: Gilead Sciences dropped 2.52% in ...

The move: Gilead Sciences dropped 2.52% in premarket trading, falling to $107.45 per share Wednesday morning. The biopharmaceutical company is up 19.34% for the year. Why: The stock's decline ...

Red Robin, which rose to prominence in the late '70s and '80s and is known for its burgers and bottomless fries, recently announced plans to close approximately 70 locations. These plans took ...

Gilead Sciences, Inc. (NASDAQ:GILD), a biopharmaceutical powerhouse known for its groundbreaking HIV treatments, stands at a critical juncture as it navigates a changing landscape in the ...

In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against the other most undervalued biotech stocks to invest in. On February 21, Jared Holz ...

--Up 43.68% from 52 weeks ago (March 20, 2024), when it closed at $73.98 --Down 9.47% from its 52-week closing high of $117.41 on March 7, 2025 --Up 68.32% from its 52-week closing low of $63.15 ...

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform ...

On a special episode (first released on March 19, 2025) of The Excerpt podcast: If you’ve paid attention to Washington politics since the start of the new Trump administration, one name is ...

Investing.com -- Shares of Gilead Sciences (NASDAQ: NASDAQ:GILD) fell 3.4% following a recent Wall Street Journal report indicating that the Health and Human Services Department is considering ...

The Health and Human Services Department is weighing plans to drastically cut funding for domestic HIV prevention, The Wall Street Journal reported.